by Rod Raynovich | Jan 26, 2010 | BIOgraph
Gilead (GILD) shares were up 6% to $47.75 after the close as the Company announced record sales and earnings. Full Year total Revenues were $7.01B up 31% over 2008. Full Year Non-GAAP EPS were $3.06 up 40% over 2008. Fourth Quarter Non-GAAP EPS were $0.93 up 49% over...
by Rod Raynovich | Jan 25, 2010 | BIOgraph
AMGN-Top line revenue slowing One of the largest biotech companies reported earnings within estimates with full year 2009 EPS of $4.91 up 8% on Revenue of $14.6B down 2%.2010 Total Revenue is expected to be in the $15.1B to $15.5B range with adjusted EPS at $5.05 to...
by Rod Raynovich | Jan 15, 2010 | BIOgraph
It is hard to believe but the Obama administration wants to open up a new political front at the last minute to squeeze the biotechnology industry after everyone thought the 12 year protection from generic biologicals was a “done deal”....
by Rod Raynovich | Jan 15, 2010 | BIOgraph
Here are some of the broader themes and market trends gleaned from Company presentations: 1.) There is a shift from small molecule drug development to biologicals and vaccines. e.g. Pfizer (PFE) 2.) “Bolt-on” acquisitions of smaller companies are being...
by Rod Raynovich | Jan 8, 2010 | BIOgraph
We will be attending the 28th Annual JPMorgan Healthcare Conference in San Francisco and reporting on various companies and news on the Genetic Engineering News WEB site (www.genengnews.com). Although we will be attending presentations of companies in all sectors we...
by Rod Raynovich | Jan 4, 2010 | BIOgraph
Robert W. Baird and Co. analyst Lawrence Neibor upgraded four medtech stocks and helped get the “January effect” in full swing. Cyberonics (CYBX), Edwards Lifescience (EW), Thoratec (THOR) and Volcano (VOLC) were all upgraded to Outperform from Neutral....
by Rod Raynovich | Dec 30, 2009 | BIOgraph
The Rayno LifeScience Biotech portfolio is up 11-15% YTD (15%+ with rebalancing as recommended). Among the big winners YTD are Regeneron (REGN) up 40%, Targacept (TRGT) up 880% and Inverness (IMA) up 72%. The portfolio included both biotech and diagnostic companies....
by Rod Raynovich | Dec 23, 2009 | BIOgraph
CompuGen, an early stage drug and diagnostic discovery Company announced today a “Discovery on Demand” therapeutic peptide collaboration with Pfizer that focuses on three peptide drugs based upon CompuGen in silico discovery platforms. The predicted...
by Rod Raynovich | Dec 21, 2009 | BIOgraph
Seasonality, deals and “healthcare reform lite” spur rally On November 18 we suggested some rebalancing in the Rayno Life Science Portfolio anticipating some year-end optimism.Today we got some help from licensing M&A and financing deals....
by Rod Raynovich | Dec 17, 2009 | BIOgraph
Well known biotech executives “face-off” in Licensing Deal gone awry Xenomics'(XNOM.PK) announced today that an ongoing internal preliminary investigation concluded that Sequenom (SQNM) willfully manipulated its Down Syndrome data in its presentations.In...
